Cohort Primary Hyperparathyroidism

计划入组 403 人 · 首次发布于 2022 年 7 月 21 日

Denosumab in Primary Hyperparathyroidism

计划入组 8 人 · 首次发布于 2012 年 3 月 20 日

Primary Hyperparathyroidism: Non-classical Manifestations

计划入组 58 人 · 首次发布于 2007 年 2 月 8 日

AZP-40XX

Primary sclerosing cholangitis(Engitix )

primary immunization-booster TB vaccine

PRIMARY PHARMACEUTICALS, INC.

United States

PRIMARY HEALTH CARE CORPORATION

Qatar

Southcoast Center For Primary & Specialty Care

United States

Hong Kong Approves Two New Drugs for Hypercalcemia Under "1+" Mechanism

Amgen Advances Phase 3 Study of Etelcalcetide for Pediatric Secondary Hyperparathyroidism

AstraZeneca's Eneboparatide Meets Primary Endpoint in Phase III Trial for Hypoparathyroidism